Literature DB >> 16393622

[Diagnosis and treatment of hepatic encephalopathy in Spain: results of a survey of hepatologists].

M Vergara-Gómez1, M Flavià-Olivella, M Gil-Prades, B Dalmau-Obrador, J Córdoba-Cardona.   

Abstract

INTRODUCTION: Hepatic encephalopathy is a common complication of cirrhosis. Recent studies have challenged the efficacy of nonabsorbable disaccharides and have reported that protein restriction may pose risks to patients with cirrhosis and hepatic encephalopathy. AIM: To determine the diagnostic and therapeutic practices of physicians treating patients with hepatic encephalopathy.
MATERIAL AND METHODS: We designed a 20-item questionnaire, which was mailed to the members of the Spanish Society for the Study of the Liver.
RESULTS: We received 128 questionnaires, completed by physicians with wide clinical experience. They reported that the most common precipitating factors in episodic encephalopathy were infections (22%), diuretics (21%), and gastrointestinal bleeding (21%). The usual treatment of episodic encephalopathy was administration of nonabsorbable disaccharides (90%) and protein restriction (52%). Patients with chronic encephalopathy were also usually treated with nonabsorbable disaccharides (94%) and protein restriction (40%). Fifty-nine percent of the hepatologists never carried out neurophysiologic or neuropsychologic assessment for the diagnosis of minimal hepatic encephalopathy.
CONCLUSION: Although their efficacy has been questioned, nonabsorbable disaccharides and protein restriction are the most commonly prescribed treatments for hepatic encephalopathy. Future studies are needed to assess the efficacy and risks of these treatments. Most hepatologists never assess minimal hepatic encephalopathy in patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393622     DOI: 10.1157/13083245

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  6 in total

1.  Treatment options for covert hepatic encephalopathy.

Authors:  Nisheet Waghray; Abhijeet Waghray; Kevin Mullen
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

2.  Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection.

Authors:  Vincenzo Citro; Graziella Milan; Francesca Saveria Tripodi; Antonio Gennari; Paolo Sorrentino; Giovanni Gallotta; Alfredo Postiglione; Giovanni Tarantino
Journal:  J Gastroenterol       Date:  2007-02-16       Impact factor: 7.527

Review 3.  Assessment of minimal hepatic encephalopathy (with emphasis on computerized psychometric tests).

Authors:  Matthew R Kappus; Jasmohan S Bajaj
Journal:  Clin Liver Dis       Date:  2012-02       Impact factor: 6.126

4.  Minimal hepatic encephalopathy matters in daily life.

Authors:  Jasmohan S Bajaj
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

5.  Predictors of minimal hepatic encephalopathy in patients with cirrhosis.

Authors:  Praveen Sharma; Barjesh C Sharma
Journal:  Saudi J Gastroenterol       Date:  2010 Jul-Sep       Impact factor: 2.485

6.  The mind and liver test: a new approach to the diagnosis of minimal hepatic encephalopathy in resource-poor settings.

Authors:  Saurav Das; Sajjadh M J Ali; James Seward; Jayanthi Venkataraman
Journal:  Int J Hepatol       Date:  2014-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.